Solid Biosciences (SLDB) Q2 2025 earnings summary

Executive summary

• Focused on gene therapy candidates for rare neuromuscular and cardiac diseases, with SGT-003, SGT-212, SGT-501, and SGT-601 in various stages of development and multiple regulatory designations granted for lead programs.

• Advanced three clinical-stage programs, expanding pipeline beyond Duchenne to include FA and CPVT, and executed over 25 agreements for proprietary AAV-SLB101 capsid technology.

• SGT-003 Phase 1/2 trial ongoing with positive interim data; SGT-212 and SGT-501 INDs cleared, with clinical trials planned for late 2025.

• Dosed 15 participants in the Phase 1/2 INSPIRE DUCHENNE trial; no treatment-emergent SAEs observed.

• Net losses continue as the company invests heavily in R&D and pipeline expansion, with no commercial revenue expected in the near term.

Financial highlights

• Net loss for Q2 2025 was $39.5 million, up from $25.1 million in Q2 2024; net loss for the first half of 2025 was $78.8 million, up from $49.4 million year-over-year.

• Research and development expenses rose 66.6% year-over-year to $32.4 million for Q2 2025, driven by SGT-003 and SGT-601 costs.

• Cash, cash equivalents, and available-for-sale securities totaled $268.1 million as of June 30, 2025, up from $148.9 million at year-end 2024, expected to fund operations into the first half of 2027.

• G&A expenses increased to $9.3 million in Q2 2025 from $8.3 million in Q2 2024, primarily due to higher personnel costs.

• Financing activities in H1 2025 raised $188.1 million, primarily from a February 2025 public offering.

Outlook and guidance

• Cash runway projected into the first half of 2027, but additional funding will be needed for continued operations and pipeline advancement beyond that period.

• Ongoing and planned clinical trials for SGT-003, SGT-212, and SGT-501 are expected to drive increased expenses.

• Regulatory discussions with FDA for SGT-003 scheduled for Q4 2025.

• Phase 1b trials for SGT-212 (FA) and SGT-501 (CPVT) expected to initiate in Q4 2025.

• No commercial product revenue anticipated for the foreseeable future.